Business Description
Grand Pharmaceutical Group Ltd
ISIN : BMG210A71198
Compare
Compare
Traded in other countries / regions
00512.Hong KongMX6A.Germany IPO Date
1995-12-19Description
Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from the PRC and also has a presence in America; Europe; Asia other than the PRC and others.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.73 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.23 | |||||
Debt-to-EBITDA | 1.12 | |||||
Interest Coverage | 14.95 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.13 | |||||
Beneish M-Score | -2.51 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 17.6 | |||||
3-Year EBITDA Growth Rate | 5.3 | |||||
3-Year EPS without NRI Growth Rate | 9.1 | |||||
3-Year FCF Growth Rate | 17.1 | |||||
3-Year Book Growth Rate | 11 | |||||
Future 3-5Y EPS without NRI Growth Rate | 10.86 | |||||
Future 3-5Y Total Revenue Growth Rate | 9.59 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 29.75 | |||||
9-Day RSI | 34.3 | |||||
14-Day RSI | 37.44 | |||||
6-1 Month Momentum % | 22.93 | |||||
12-1 Month Momentum % | 8.54 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.22 | |||||
Quick Ratio | 0.98 | |||||
Cash Ratio | 0.43 | |||||
Days Inventory | 107.55 | |||||
Days Sales Outstanding | 47.47 | |||||
Days Payable | 90.76 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 6.09 | |||||
Dividend Payout Ratio | 0.38 | |||||
3-Year Dividend Growth Rate | 13.4 | |||||
Forward Dividend Yield % | 6.09 | |||||
5-Year Yield-on-Cost % | 6.04 | |||||
3-Year Average Share Buyback Ratio | 0.5 | |||||
Shareholder Yield % | 8.7 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 59 | |||||
Operating Margin % | 25.14 | |||||
Net Margin % | 22.75 | |||||
FCF Margin % | 18.2 | |||||
ROE % | 16.52 | |||||
ROA % | 10.73 | |||||
ROIC % | 11.23 | |||||
ROC (Joel Greenblatt) % | 76.71 | |||||
ROCE % | 18.67 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 6.26 | |||||
Forward PE Ratio | 7.16 | |||||
PE Ratio without NRI | 6.36 | |||||
Shiller PE Ratio | 11.94 | |||||
Price-to-Owner-Earnings | 8.65 | |||||
PEG Ratio | 0.5 | |||||
PS Ratio | 1.43 | |||||
PB Ratio | 0.99 | |||||
Price-to-Tangible-Book | 1.2 | |||||
Price-to-Free-Cash-Flow | 7.84 | |||||
Price-to-Operating-Cash-Flow | 6.23 | |||||
EV-to-EBIT | 5.24 | |||||
EV-to-EBITDA | 5.24 | |||||
EV-to-Revenue | 1.5 | |||||
EV-to-FCF | 8.11 | |||||
Price-to-Projected-FCF | 0.57 | |||||
Price-to-DCF (Earnings Based) | 0.18 | |||||
Price-to-DCF (FCF Based) | 0.56 | |||||
Price-to-Median-PS-Value | 0.8 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.57 | |||||
Price-to-Graham-Number | 0.62 | |||||
Earnings Yield (Greenblatt) % | 19.08 | |||||
FCF Yield % | 12.8 | |||||
Forward Rate of Return (Yacktman) % | 21.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Grand Pharmaceutical Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil HK$) | 10,587.34 | ||
EPS (TTM) (HK$) | 0.687 | ||
Beta | 0.71 | ||
Volatility % | 32.34 | ||
14-Day RSI | 37.44 | ||
14-Day ATR (HK$) | 0.134027 | ||
20-Day SMA (HK$) | 4.44 | ||
12-1 Month Momentum % | 8.54 | ||
52-Week Range (HK$) | 3.17 - 5.31 | ||
Shares Outstanding (Mil) | 3,501.81 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Grand Pharmaceutical Group Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Grand Pharmaceutical Group Ltd Stock Events
Event | Date | Price(HK$) | ||
---|---|---|---|---|
No Event Data |
Grand Pharmaceutical Group Ltd Frequently Asked Questions
What is Grand Pharmaceutical Group Ltd(HKSE:00512)'s stock price today?
The current price of HKSE:00512 is HK$4.30. The 52 week high of HKSE:00512 is HK$5.31 and 52 week low is HK$3.17.
When is next earnings date of Grand Pharmaceutical Group Ltd(HKSE:00512)?
The next earnings date of Grand Pharmaceutical Group Ltd(HKSE:00512) is .
Does Grand Pharmaceutical Group Ltd(HKSE:00512) pay dividends? If so, how much?
The Dividend Yield %  of Grand Pharmaceutical Group Ltd(HKSE:00512) is 6.09% (As of Today), Highest Dividend Payout Ratio of Grand Pharmaceutical Group Ltd(HKSE:00512) was 0.38. The lowest was 0.18. And the median was 0.21. The  Forward Dividend Yield % of Grand Pharmaceutical Group Ltd(HKSE:00512) is 6.09%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |